Also, the insulin signaling pathway appears to be involved in this phenomenon, because daf-2 mutants are resistant to the development of sarcopenia and associated declines in motility during aging (Duhon and Johnson, 1995; Herndon et al., 2002; Glenn et al., 2004). This evidence concerns the gene INS and sarcopenia.